ABLS - ETF AI Analysis

Top Page

Abacus FCF Small Cap Leaders ETF (ABLS)

Rating:70Neutral

Price Target:―

ABLS, the Abacus FCF Small Cap Leaders ETF, earns a solid overall rating driven mainly by strong holdings like Harmony Biosciences and LCI Industries, which combine healthy financial performance, positive earnings calls, and supportive technical trends. These strengths are partly offset by weaker names such as Oscar Health, where profitability and valuation challenges weigh on the fund, and by some holdings showing bearish or overbought technical signals. Investors should also note that the fund is concentrated in a relatively small group of small-cap companies, which can increase volatility and stock-specific risk.

Positive Factors

Strong Lead Holding

The largest position, Argan, has shown strong gains this year, providing a meaningful boost to the fund’s results.

Multiple Sector Exposure

Holdings spread across technology, health care, industrials, financials, and consumer sectors help reduce reliance on any single industry.

Moderate Expense Ratio

The fund’s fee is reasonable for a specialized small-cap strategy, allowing investors to keep more of their potential returns.

Negative Factors

Recent Weak Short-Term Performance

The ETF has experienced weak returns over the past one and three months, which may signal near-term volatility or pressure on small-cap stocks.

High Stock Concentration

A small number of holdings, especially the top position, make up a significant share of the portfolio, increasing the impact of any single stock’s performance.

Limited Geographic Diversification

With almost all assets invested in U.S. companies, the fund offers little protection from risks specific to the U.S. market.

ABLS vs. SPDR S&P 500 ETF (SPY)

AUM988.65K

RegionNorth America

Expense Ratio0.39%

Beta0.77

IssuerAbacus

Inception DateFeb 18, 2025

Dividend YieldN/A

Asset ClassEquity

Index TrackedAbacus FCF Small Cap Leaders Index - Benchmark TR Gross

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume83

30 Day Avg. Volume61

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

24.54

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering50

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

ABLS Summary

The Abacus FCF Small Cap Leaders ETF (ABLS) tracks the Abacus FCF Small Cap Leaders Index, focusing on smaller U.S. companies with strong profits and healthy cash flow. It holds a mix of sectors like technology, health care, industrials, and financials, with top positions in firms such as CommVault Systems and Oscar Health. Investors might consider ABLS if they want growth potential from small-cap stocks while still emphasizing financially solid businesses and diversification across many industries. However, small-cap stocks can be more volatile, so the ETF’s price can move up and down more sharply than the overall market.

How much will it cost me?The Abacus FCF Small Cap Leaders ETF (ABLS) has an expense ratio of 0.39%, meaning you’ll pay $3.90 per year for every $1,000 invested. This is slightly higher than average for passively managed ETFs because it focuses on a niche area of small-cap stocks with strong financial metrics.

What would affect this ETF?The Abacus FCF Small Cap Leaders ETF could benefit from strong growth in the U.S. economy, particularly in sectors like technology and health care, which make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as small-cap companies often rely on borrowing to fund growth, or if economic conditions weaken, which could impact consumer spending and industrial activity. Regulatory changes in key sectors like financials or health care could also influence performance positively or negatively.

ABLS Top 10 Holdings

ABLS leans heavily into U.S. small caps, with a clear tilt toward tech and health care names that can throw off solid cash flow. Argan is the star of the show, rising strongly and doing much of the heavy lifting for recent returns, while LCI Industries and PJT Partners are also pulling their weight with steady to rising momentum. On the flip side, CommVault Systems has been lagging, and Oscar Health looks mixed, occasionally tripping over profitability concerns. Overall, the fund is concentrated in a handful of U.S. small-cap leaders rather than big household names.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
AGX	Argan	11.32%	$111.96K	$5.74B	178.38%	73 Outperform
COLL	Collegium Pharmaceutical	5.11%	$50.51K	$1.43B	52.66%	71 Outperform
APAM	Artisan Partners	4.32%	$42.72K	$3.54B	0.64%	73 Outperform
LCII	LCI Industries	4.23%	$41.81K	$3.75B	40.06%	79 Outperform
ENVA	Enova International	3.52%	$34.77K	$3.67B	33.96%	71 Outperform
HRMY	Harmony Biosciences Holdings	3.23%	$31.98K	$2.06B	-8.03%	81 Outperform
HCSG	Healthcare Services	3.18%	$31.44K	$1.50B	96.86%	72 Outperform
CVLT	CommVault Systems	3.14%	$31.00K	$3.84B	-52.79%	65 Neutral
PJT	PJT Partners	2.90%	$28.71K	$7.49B	-12.34%	71 Outperform
DNOW	Now	2.88%	$28.48K	$3.00B	-5.94%	76 Outperform

ABLS Technical Analysis

Technical Analysis Sentiment

Negative

Last Price―

Price Trends

50DMA

20.17

Negative

100DMA

20.26

Negative

200DMA

20.44

Negative

Market Momentum

MACD

-0.26

Positive

RSI

38.19

Neutral

STOCH

49.67

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ABLS, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 19.79, equal to the 50-day MA of 20.17, and equal to the 200-day MA of 20.44, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 38.19 is Neutral, neither overbought nor oversold. The STOCH value of 49.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABLS.

ABLS Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
ABLS	―	―	$988.65K	0.39%	―
AFSM	―	―	$82.09M	0.75%	―
STXK	―	―	$75.27M	0.18%	―
BKSE	―	―	$75.03M	0.04%	―
FLQS	―	―	$70.86M	0.35%	―
SYZ	―	―	$62.55M	0.74%	―

Performance Comparison

ABLS

Abacus FCF Small Cap Leaders ETF

19.19

-2.37

-10.99%

AFSM

First Trust Active Factor Small Cap ETF

―

STXK

Strive 2000 ETF

―

BKSE

BNY Mellon US Small Cap Core Equity ETF

―

FLQS

Franklin LibertyQ U.S. Small Cap Equity ETF

―

SYZ

Lazard US Systematic Small Cap Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents